Puerto Rico Science Technology Trust And Team Wins $1M National Science Foundation Engines Development Award
Kannapolis, North Carolina – Bright Path Laboratories, a US-based advanced drug development and manufacturing company is proud to announce that they were chosen to participate as a collaborator in an NSF Innovation Engines Development Award granted by the National Science Foundation (NSF) yesterday.
The NSF Engine awarded to The Puerto Rico Science, Technology & Research Trust (‘Trust’) (https://prsciencetrust.org/nsf/) has been awarded one million dollars ($1M) from the U.S. National Science Foundation's Regional Innovation Engines, or “NSF Engines.” The Trust is among 44 unique teams to receive one of the first-ever NSF Engines Development Awards, which aims to help partners collaborate to create economic, societal, and technological opportunities for significant growth for their regions.
The NSF Engine Development Award “Advancing Biopharmaceutical Technologies and Manufacturing Practices (P.R.)" is the first step to enable to lay the groundwork for establishing a new NSF Engine in Puerto Rico, developing its structure and scope, and establishing partnerships to advance biopharmaceutical technologies and manufacturing practices. At the end of the 2-year Development Award, the expectations are for the team to be well-prepared to establish an NSF Engine in the Nascent Phase under an NSF Engines Award of up to $160 million for up to 10 years.
The team sees this Engine as immediately having a measurable impact on the economy, increase the number of jobs, and develop workforce training strategies to propel Puerto Rico to be the largest – and most agile biopharma hub in the US, even in the early stages of the Engine program.
“The necessity to invest in innovative pharmaceutical manufacturing in the United States has never been greater. Bright Path’s state of the art continuous flow advanced manufacturing platform is an integral part of our nation’s supply chain readiness initiative,” said Tony Quinones, Co-Founder and Chief Executive Officer of Bright Path Laboratories. “Bright Path has spent the last few years building our U.S. facilities where we currently develop and manufacture pharmaceutical ingredients. We are very pleased that NSF has chosen the Trust as an awardee and excited to expand and solve the immediate and long-term challenges in our medicinal supply chain through our transformative technology.”
About Bright Path Laboratories
Bright Path Laboratories, Inc. brings its AI-enabled, advanced continuous manufacturing technology to the pharmaceutical industry where its novel chemical production techniques can have a significant impact in solving some of today’s biggest challenges: reestablishing and improving the resiliency of pharmaceutical domestic supply chains, and accessibility and affordability of medicine. The Company uses its proprietary and patented STT® reactor for continuous and on-demand production of specialty chemicals, key starting materials (KSMs) and intermediates, and active pharmaceutical ingredients (APIs) in North America with an emphasis on sustainable Green Chemistry. www.brightpathlabs.com
Media Contact:
Jennifer Burgess
jenniferburgess@brightpathlabs.com